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AbstrACt
Introduction Vaccine hesitancy is a complex public health 
issue referring to concerns about the safety, efficacy 
or need for vaccination. Relatively little is known about 
vaccine hesitancy in Switzerland. This ongoing study 
(2017–2021) focuses on biomedical and complementary 
and alternative medicine (CAM) providers and their 
patients since healthcare professionals play important 
roles in vaccination decision- making. This national 
research programme seeks to assess the sociocultural 
determinants of vaccine hesitancy regarding childhood 
and human papillomavirus vaccines in Switzerland. We 
aim to provide a detailed characterisation of vaccine 
hesitancy, including CAM and biomedical perspectives, 
patient–provider interactions, and sociocultural factors, 
to establish the mediating effects of vaccine hesitancy 
on underimmunisation, and to design an intervention 
to improve vaccination communication and counselling 
among physicians, parents and adolescents.
Methods and analysis Our transdisciplinary team 
employs a sequential exploratory mixed- methods study 
design. We have established a network of more than 150 
medical providers across Switzerland, including more than 
40 CAM practitioners. For the qualitative component, we 
conduct interviews with parents, youth, and biomedical 
and CAM providers and observations of vaccination 
consultations and school vaccination information sessions. 
For the quantitative component, a sample of 1350 parents 
of young children and 722 young adults (15–26 years) 
and their medical providers respond to questionnaires. We 
measure vaccine hesitancy with the Parent Attitudes about 
Childhood Vaccines 15- item survey and review vaccination 
certificates to assess vaccination status. We administer 
additional questions based on findings from qualitative 
research, addressing communication with medical 
providers, vaccine information sources and perceptions of 
risk control vis-à-vis vaccine- preventable diseases. The 
questionnaires capture sociodemographics, political views, 
religion and spirituality, and moral foundations.
Ethics and dissemination The study was approved by 
the local ethics committee. The results will be published 
in peer- reviewed journals and disseminated to healthcare 
professionals, researchers and the public via conferences 
and public presentations.
IntroduCtIon
Vaccines are ranked among the greatest public 
health achievements.1 Extensive evidence 
documents the efficacy, minimal side effects 
and cost- effectiveness of vaccines recom-
mended by numerous national immunisa-
tion programmes, including that of the Swiss 
Federal Office of Public Health (FOPH).2 3 
Despite public health successes of vaccines, a 
large number of people in Western countries 
express concerns about vaccine safety, effi-
cacy or need, a behaviour now referred to as 
vaccine hesitancy.4–6
Vaccine hesitancy has gained increasing 
attention from the global public health 
strengths and limitations of this study
 ► A novelty of this research includes its large sample 
of complementary and alternative medicine (CAM) 
and biomedical providers, with consideration given 
to their vaccination perspectives and interactions 
with their patients.
 ► The study emphasis on CAM providers is important 
since previous studies have shown an association 
between CAM use and vaccine hesitancy as well as 
high patient demand for CAM in Switzerland.
 ► The sequential exploratory mixed- method study de-
sign and transdisciplinary nature of this study pro-
vide further insights into the relationships between 
CAM and biomedical providers and vaccine hesitan-
cy and uptake, with the qualitative methods and re-
sults having informed the design of the quantitative 
questionnaire.
 ► Although the methodological approach to recruit 
patients via medical providers is advantageous be-
cause it allows for the examination of effects of pro-
vider characteristics on patient vaccination beliefs 
and behaviours, it limits our results because popula-
tions that do not regularly see medical providers are 
under- represented in our data.
 ► Furthermore, the data do not provide nationally rep-
resentative results.
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community. In August 2015, the WHO referred to 
vaccine hesitancy as a ‘growing challenge for immuniza-
tion programs’,7–9 responding to a 2014 report10 from the 
WHO Strategic Advisory Group of Experts on Immunisa-
tion. In early 2019, WHO listed vaccine hesitancy among 
the top 10 threats to global health, citing a global need to 
address rising rates of measles and to eliminate cervical 
cancer by ramping up efforts to increase coverage with 
the human papillomavirus (HPV) vaccine.11
While the importance of vaccine hesitancy is widely 
acknowledged, its determinants are incompletely under-
stood and merit further investigation.4 Researchers 
having conducted a systematic review on determinants 
of vaccine hesitancy from a global perspective found that 
there was ‘no universal algorithm’ (p2155) and recom-
mended context- specific research.4 Other researchers 
have argued in favour of cross- disciplinary research, 
stating ‘Vaccine hesitancy and acceptance are complex, 
multi- faceted issues. Our understanding of them must be 
complex and multifaceted as well’ (p279).12
When vaccine hesitancy leads to underimmunisation, 
which we define as delaying or omitting some or all offi-
cially recommended vaccines, this provides an example 
of the underuse of a medical intervention considered 
to be safe and effective. Underimmunisation is a public 
health concern because it can reduce population protec-
tion, also referred to as herd immunity, towards certain 
potentially dangerous infectious agents and increases the 
risk of disease outbreaks.
Studies suggest that personal, social12 13 and local 
cultural6 networks are important determinants of vacci-
nation decisions, in particular among those who under-
vaccinate. Furthermore, people’s sources of information 
on health and vaccination- related information can play 
important roles in vaccination choices, with recent 
research pointing to the importance of ‘information over-
load’, ‘misinformation’ and higher levels of indecision 
among parents, particularly given the wide availability of 
(mis)information on the internet.14–18
Additionally, parent and provider perspectives that differ 
from official public health recommendations need to be 
considered in order to understand vaccine hesitancy.12 
These may include intuitive rather than analytical cogni-
tive styles, reluctance to consider the evidence suggesting 
vaccine safety/efficacy, and lowered willingness to trust 
information delivered by public health authorities, as 
shown in an adherence to complementary and alternative 
medicine (CAM)- oriented health values and preference 
of CAM over biomedicine.19 Studies also suggest that 
underimmunisation and usage of CAM are determined 
by similar factors, such as alternative concepts of body, 
immunity, risk perception, antiauthoritarian orientation, 
and distrust of biomedical establishment and the phar-
maceutical industry.6 19 Some of these associations may 
in part be due to confounding factors, such as higher 
income and education and distrust of medical systems.20 
Other sociomedical trends may also play a role in height-
ened patient participation in decision- making, such as 
postmodern medicine,21 characterised by risk culture,22 
healthism23 and patients activating more agency in 
healthcare decisions.24 Finally, research findings suggest 
limitations to the efficacy of the evidence- based strategies 
that have generally been employed by health authorities 
over the past decades to increase vaccination rates.19
A key determinant of patient vaccination decision- 
making seems to be the attitudes, behaviour and knowl-
edge of their medical provider.25–27 Important factors 
include the amount of time providers spend discussing 
vaccinations, their communication styles and the informa-
tion available to providers.28–31 As an example of medical 
providers’ influence on vaccination decisions, one study 
in the USA found that primary care providers with many 
parents who had vaccine exemptions for their children 
were more likely to have concerns about vaccine safety 
and were less likely to perceive individual and commu-
nity benefits of vaccinations than primary care providers 
treating fewer children with vaccine exemptions.25 A qual-
itative study into vaccination decision- making in the USA 
highlighted the importance of trust between healthcare 
professionals and parents.32 Finally, the way that providers 
broach vaccination during consultations can have a 
determinative role in vaccination uptake, with one study 
recommending further investigation of participatory (ie, 
‘What do you think about doing shots today?’) versus 
presumptive (ie, ‘Today, we are going to do some shots’) 
approaches during patient–provider interactions.26
the swiss context
In Switzerland, childhood vaccinations are usually given 
by private practitioners, predominantly paediatricians 
and general internists. There is no national mandate for 
vaccination in non- epidemic settings in Switzerland and 
no national vaccination registry. Despite this, vaccina-
tion coverage in Switzerland is high overall.33 The FOPH 
makes vaccination recommendations and distinguishes 
between basic and and complementary vaccinations. 
(Basic vaccines are defined as ‘essential to individual and 
public health, and offer a level of protection that is indis-
pensable to people’s well- being (eg, diphtheria, tetanus, 
pertussis, polio, MMR (mumps, measles, rubella), HBV (, 
HBV (hepatitis B), HPV (human papillomavirus)’ (pA51). 
Complementary vaccines are defined as being able to ‘maxi-
mize individual protection and are meant for individuals 
seeking protection from well- defined risks (eg, conjugate 
pneumococcal vaccine and conjugate meningococcus 
C vaccine)’ (pA51).34) Both basic and complementary 
vaccines are reimbursed by basic mandatory health insur-
ance when the official vaccination schedule is respected.
Given the absence of a national vaccination registry, 
the FOPH measures Swiss vaccination coverage at regular 
intervals.35 Vaccination programmes and their imple-
mentation vary between the 26 cantons.34 For example, 
children from the French- speaking and Italian- speaking 
cantons have on average higher rates of measles vaccina-
tion coverage than in German- speaking cantons.36
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Cantonal coverage levels for HPV vaccination range 
from 79% (Valais) to 19% (Appenzell Innerrhoden) for 
two doses of HPV vaccine. HPV coverage estimates only 
include 16- year- old girls and estimates for boys are not 
yet available.37 The most common reasons for women not 
being vaccinated against HPV, according to a 2014 survey, 
included being too old, lack of information, fear of side 
effects, being against vaccination in general or against 
HPV vaccination only, HPV vaccination felt to be unnec-
essary, and simple logistical issues,38 with 7% and 6% of 
women not vaccinated against HPV reporting that the 
physician or friends/family recommended against HPV 
vaccine, respectively. Further research has shown that 
living in cantons with school- based vaccination increases 
uptake of HPV vaccination.39 40 However, spatial varia-
tion modelling has shown that variables such as political 
opinion, religion and community opinion might be addi-
tional determinative factors in the presence of school- 
based vaccination programmes.40 This suggests further 
research is needed to better understand vaccine hesitancy 
and school- based vaccination programmes in Switzerland.
Vaccine hesitancy and underimmunisation seem to 
be specific to certain population subgroups.34 41 42 For 
example, in Switzerland, measles cases, small epidemics43 
and underimmunisation cluster around children 
attending anthroposophic (ie, Rudolf Steiner, Waldorf) 
schools and around certain providers of CAM.41 One cross- 
sectional survey (n=1007) was administered for paediatric 
patients in an urban paediatric emergency department 
in German- speaking Switzerland. Researchers found 
that those who did not fully accept basic vaccinations 
were more frequently CAM users than non- users, which 
researchers point to as reflecting parent wishes rather 
than physicians’ recommendations.44 This relationship 
merits further investigation and discussion.
Studies in Switzerland show high rates of CAM use and 
favourable opinions, with 25% of Swiss survey respon-
dents aged 15 and older of the 2007 Swiss Health Survey 
stating that they had used CAM in the previous year.45 46 
Other researchers assessed surveys conducted among the 
general population, doctors, hospitalised patients and 
obstetric institutions and found that approximately 50% 
of the Swiss population had used CAM and that 85% of 
the population would like the cost of CAM to be covered 
by basic health insurance.47 CAM providers in Switzerland 
are often physicians trained in conventional medicine 
who have then obtained additional CAM training,48 and 
basic mandatory health insurance reimburses four CAM 
services when provided by licensed physicians: (1) anthro-
posophic medicine, (2) traditional Chinese medicine and 
acupuncture, (3) homeopathy, and (4) phytotherapy.49
rationale for the research project
The scientific literature points to existing research gaps, 
such as a lack of detailed information on vaccine hesi-
tancy, patient–provider communication in Switzerland, 
vaccination information sources and relations to the high 
prevalence of CAM use in Switzerland. This highlights the 
interest in an exploratory mixed- method methods study 
investigating the vaccination perspectives and practices 
of patients and both CAM and biomedical providers. 
Our research focuses specifically on childhood vaccina-
tions recommended in Switzerland50 and on the vaccina-
tion against HPV, which is included in the Swiss FOPH 
recommendations for all adolescents 11–14 years of age. 
However, vaccination against HPV is recommended as a 
routine vaccination for females and as a complementary 
vaccination for males.50
objectives and aims
 ► To explore vaccine hesitancy and provide a detailed 
characterisation of its health system, patient–provider 
interaction, health communication, informa-
tion sources, decision- making process, and demo-
graphic, geographical and sociocultural correlates in 
Switzerland.
 ► To assess the sociocultural and health system 
determinants of vaccine hesitancy and underim-
munisation with childhood and HPV vaccines in 
Switzerland. This objective additionally aims at estab-
lishing the mediating effects of vaccine hesitancy on 
underimmunisation.
 ► To use the knowledge gained as the necessary back-
ground to design and submit a pilot intervention and 
to design tailored interventions to address vaccine 
hesitancy in Switzerland.
MEthods And dEsIgn
Our research takes place in the setting of an ongoing 
Swiss national research programme (National Research 
Programme 74). The study protocol underwent 
successful peer review. For further information, refer 
to http://www. nfp74. ch/ en/ projects/ out- patient- care/ 
project- tarr. It represents a transdisciplinary51 collab-
oration that views vaccine hesitancy as a complex, 
multifaceted phenomenon. Rosenfield51 explains how 
transdisciplinary research can be conducted, particularly in 
health research: ‘Representatives of different disciplines 
are encouraged to transcend their separate conceptual, 
theoretical, and methodological orientations in order to 
develop a shared approach to the research, building on 
a common conceptual framework. Such a framework can 
be used to define and analyze the research problem and 
develop new approaches for health care that more closely 
represent the historical and present- day reality in which 
health problems are situated’ (p1351). The study team is 
composed of researchers and medical practitioners with 
a varied range of backgrounds and training. An infectious 
disease specialist and internist leads the core study team, 
which includes sociologists, anthropologists, and public 
health specialists who collaborate closely with a steering 
committee composed of clinicians trained in biomedi-
cine and CAM, a researcher in anthroposophic medicine, 
public health experts and policy makers.
The project applies mixed methods through the use 
of a sequential exploratory design in order to study vaccine 
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Figure 1 Study overview. CAM, complementary and 
alternative medicine; HPV, human papillomavirus.
hesitancy across Switzerland, meaning that we first begin 
with qualitative methods in order to inform the tools used 
for the data collection through quantitative methods.52 
An overview of the study design is shown in figure 1. 
We recruit participants from the three major language 
regions of Switzerland (German- speaking, French- 
speaking and Italian- speaking) in order to examine vacci-
nation decision- making throughout the country.
The qualitative and quantitative phases of the project 
both involve recruitment in medical providers’ offices 
and interviewers with medical providers. For this purpose, 
we established a network of participating providers via the 
FOPH’s Swiss Sentinel Surveillance Network and through 
direct recruitment by our research team. Our research 
team and advisory board include both CAM and biomed-
ical providers, who have helped recruit their colleagues 
for this project, sharing recruitment documents (ie, invi-
tation letters and study flyers), making telephone calls 
and employing snowball sampling. Ongoing provider 
recruitment efforts have enabled us to develop a network 
of over 150 CAM and biomedical providers from 21 of the 
26 cantons and all three language regions in Switzerland.
For the study’s qualitative component, we conduct 
semistructured, indepth interviews with parents, youth, 
and biomedical physicians and CAM providers. We also 
observe vaccination consultations with parents and 
providers and HPV information events in schools. For the 
study’s quantitative component, we recruit participants 
from the practices of the network of CAM and biomed-
ical providers across Switzerland and perform quantita-
tive telephone interviews with parents of children 0–11 
years of age and youth aged 15–26 years. We also inter-
view the participating providers. The collection of infor-
mation about vaccine hesitancy from providers and their 
patients allows for a comparison of their perceptions of 
vaccinations.
Some providers participate in both the qualitative and 
quantitative research components, while most participate 
only in the quantitative phase. Importantly, our team had 
already established trusting relationships with a number 
of CAM physicians by the time of grant submission. These 
contacts have been crucial in expanding our network of 
CAM providers in Switzerland for the quantitative study 
phase.
Qualitative methods
The qualitative methods of this research allow us to gain 
deeper insight into parent and youth vaccination decision- 
making and patient–provider interactions about vaccina-
tion in general practice settings. The qualitative methods 
additionally further our understanding about public 
health gaps in vaccination implementation programmes 
in Switzerland by paying attention to how participants 
discuss the Swiss health system in relation to vaccination. 
Finally, the qualitative methods inform the design of the 
quantitative study component tools.
The transdisciplinary research team drafted interview 
guides and medical consultation observation guides to be 
used as qualitative study tools. The interview guides were 
written based on relevant vaccine hesitancy literature and 
guide researchers through semistructured interviews with 
participants through the use of open- ended questions. 
Semistructured interviews involve researchers asking the 
same questions systematically to all participants, but allow 
the option for researchers to probe further by asking addi-
tional questions about themes emerging during the inter-
view. The medical consultation observation guides allow 
researchers to systematically focus on items of interest 
highlighted in vaccine hesitancy literature on patient–
provider interactions.28–31 Both the interview guides and 
the observation guides were piloted for coherence and 
clarity.
An important concept in qualitative research to deter-
mine sample sizes is the concept of saturation, which indi-
cates that similar results are consistently collected during 
data collection and adequately address the research ques-
tions at hand. When saturation has been attained in qual-
itative research, researchers can reasonably expect similar 
results if the research process were to continue.53 54 We 
expect to reach data saturation with the number of quali-
tative face- to- face interviews and observations mentioned 
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below, but the qualitative nature of this approach allows us 
flexibility in adjusting the amount of data to be collected.
Qualitative interviews with biomedical and CAM providers
We conduct indepth, semistructured qualitative inter-
views with at least 15 CAM providers and at least 15 
biomedical physicians in providers’ offices. Interview 
questions are organised by theme, including (1) contex-
tual information about the providers (ie, type of training, 
type of medicine practised, years of clinical experience 
and descriptions of the types of patients they treat); 
(2) questions about interactions with their patients and 
typical vaccination consultations (ie, amount of time 
spent discussing vaccination, communication strate-
gies and perceptions about communication training); 
and (3) views and perspectives on medicine, immunity 
and the body (ie, information sources on vaccinations, 
perceptions about their advantages and disadvantages, 
‘natural acquired immunity’ vs vaccine- acquired immu-
nity, public health benefits compared with individual 
choice considerations, and vaccination rates and public 
health approaches in Switzerland). The interviews are 
audio- recorded and transcribed verbatim. If participants 
request transcriptions, we provide them so that they may 
clarify anything that they discussed.
Ethnographic observations of vaccination consultations
We observe a total of 30 vaccination consultations (15 
with CAM providers, 15 with biomedical providers) with 
10 different providers (5 CAM, 5 biomedical). We ask 
willing providers to allow us to observe consultations 
during which they discuss vaccination with parents for the 
first time. Prior to consultation observations, researchers 
discuss how they are conducted, with both providers and 
patients having the option to not be observed. In cases of 
reluctance to participate, potential participants are able 
to ask questions about the study, and researchers provide 
them with written information about the study. We do not 
observe participants who do not wish to participate in the 
study. To date, providers not wishing to be observed are 
uncommon, and no patients have refused being observed. 
Providers explained these rare refusals by describing how 
they did not wish researchers’ observations to disturb the 
natural flow of consultations with patients, not having 
enough time or not seeing enough patients with whom 
they discuss vaccination for the first time on a daily basis.
Researchers take ethnographic field notes about the 
observation in field journals in order to document what 
happens during the interactions. They then fill out a 
medical consultation observation guide, which prompts 
them to record information about patients and providers, 
the reason for the consultation, who initiated the vacci-
nation discussion, if vaccinations were discussed in a 
participatory or presumptive manner, questions asked 
by patients, if and how patients expressed hesitancy 
towards vaccination, researchers’ perceptions of the 
patients’ ability to understand the vaccination discus-
sion, the vaccination decision, the amount of time spent 
discussing vaccination, information source materials, and 
the researchers’ perceptions of the mood, emotions and 
communication between parents and providers. After 
observing the medical consultations, researchers use 
ethnographic field notes and the observation guide as 
the basis to write observations into a descriptive narrative 
format of each observed consultation.
Qualitative interviews with parents
We conduct indepth qualitative interviews with 30 
vaccine- hesitant parents and 10 parents who vaccinate 
according to the FOPH vaccination schedule. Inter-
views are conducted in their homes or in a place of 
their choosing, such as a coffee shop. We purposefully 
sample more vaccine- hesitant parents, particularly those 
who consult CAM providers for their children, since an 
important study assumption is that vaccine hesitancy, 
underimmunisation by parents and their usage of CAM 
are codetermined. We ask parents questions thematically 
about (1) family composition and parental roles (ie, work, 
childcare, child healthcare decisions); (2) children’s 
health, healthcare and lifestyle (ie, types of healthcare 
professionals parents consult for their children, health 
beliefs and practices, CAM use, preventive practices, and 
so on); (3) immunisation status of the children with the 
support of vaccination booklets during the interview; (4) 
vaccination perspectives (views on individualised vacci-
nation calendars and views on the public health benefits 
or consequences of vaccination); and (5) vaccination 
experiences (the vaccination decision- making process, 
vaccination discussions with healthcare professionals and 
others, and perceptions of social pressure to vaccinate or 
not vaccinate).
Qualitative research focus on HPV vaccination: youth and parents
There are limited published data on adolescent female 
views on HPV vaccine38 55 and no data on adolescent 
male views on HPV vaccine in Switzerland. Therefore, we 
also conduct qualitative indepth interviews with approxi-
mately 40 youth (approximately 25 males and 15 females) 
recruited through the HPV quantitative research discussed 
below. Interviews take place in participants’ homes or in a 
place of their choosing, such as a coffee shop. We purpo-
sively sample more male youth since there is no literature 
on male perspectives on HPV in Switzerland, and HPV 
vaccination recommendations are more recent for males 
than females. If youth provide their consent, the parents 
of 15 youth are interviewed separately and in family 
focus group discussions (FGD) together with the youth. 
Themes of the interviews and FGD include (1) questions 
relating to family composition and parental roles; (2) 
youth health, healthcare and lifestyle (ie, types of health-
care, professionals young adults/adolescents consult, 
health beliefs and practices, CAM use, preventive prac-
tices, and so on); (3) HPV immunisation status; (4) HPV 
perspectives; and (5) HPV vaccination experiences and 
the vaccination decision- making process. This last theme 
focuses particularly on discussions with parents, friends, 
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acquaintances, significant others, potential sexual part-
ners, information sources, schools’ roles in providing 
vaccination information, and how or if the youth ever felt 
any social pressure to vaccinate or not vaccinate against 
HPV.
Qualitative research focus on HPV vaccination: schools and public 
health officials
We observe 10 school information activities about HPV 
vaccines in three to four cantons. We choose cantons 
based on convenience in terms of access and ethical clear-
ance to conduct ethnographic observations for research 
purposes. Researchers attend school- based events during 
which the HPV vaccination is presented to youth. In class-
rooms, our researchers explain to students and instruc-
tors that we are there to observe and take notes on the 
content of the discussions as part of a study that examines 
how this type of information is communicated in schools. 
No identifying information is documented or included 
in any dissemination of research results. Observation 
notes are documented in field journals and subsequently 
written into a descriptive narrative format.
We purposively sample an estimated two to three public 
health officials from the FOPH, two to three cantonal 
authorities, and approximately five school physicians 
for expert interviews (n=10–15) in order to gain further 
information about how recommendations are made, 
discussed, planned and implemented from a public 
health perspective. Interviews focus on perceptions of the 
implementation of vaccination programmes from public 
health authority perspectives and are informed by specific 
questions from our qualitative enquiries.
Vaccination information sources
In order to better understand how information sources 
affect parent, youth and provider decision- making 
processes, we document and analyse sources of informa-
tion that they discuss during the qualitative and quanti-
tative interviews and medical consultation observations 
using both thematic analysis56 and critical discourse 
analysis.57–59 Since the internet’s role in vaccine- related 
decision- making is well documented in the litera-
ture,14 15 60–62 we are particularly interested in parents’ 
and youth’s use of and interactions with internet sources.
Qualitative data analysis
The following are the primary research questions 
guiding the conduct of the qualitative research: (1) How 
do parents and youth make vaccination decisions? (2) 
How do medical providers, both CAM and biomedical, 
consider what vaccination recommendations to make 
to their patients? (3) How do medical providers discuss 
vaccination with parents and youth? (4) How are vacci-
nation implementation programmes envisaged from a 
public health perspective?
We use the Consolidated criteria for Reporting Qual-
itative research checklist63 as guidelines for reporting 
items of interest in the presentation of qualitative results. 
Since we work with diverse sources of qualitative data, 
we use the framework method64 and grounded theory, 
particularly constructivist grounded theory as outlined by 
Charmaz,65 as guiding principles for our analysis. This 
allows our research team to structure an analytical 
framework throughout qualitative data analysis with the 
use of sensitising concepts and to code data into relevant 
research themes while still being open to including cate-
gories and themes that emerge through qualitative data 
collection and analysis. Data are coded primarily by the 
interviewers, with coded segments being discussed with 
various members of the research team.
Sensitising concepts are used in qualitative research 
in order to guide researchers to selectively focus on 
emerging themes and categories relevant to the research 
questions66; for this research, sensitising concepts include 
patient–provider interactions, provider and patient inter-
action with information sources, health beliefs and prac-
tices, and interactions with and perceptions of the Swiss 
health system.
With the focus on patient–provider interactions in 
vaccination decision- making, the choice to research these 
questions by interviewing parents, youth and medical 
providers and observing vaccination consultations allows 
us to triangulate our qualitative data in order to account 
for the ‘multiple realities’ of medical consultations.67 
Finally, in order to fully appreciate the complexity of how 
people interact with health information in order to make 
vaccination choices, we will conduct both thematic anal-
ysis56 and critical discourse analysis57–59 of any sources of 
information mentioned as being important or determi-
native during vaccination discussions. A first manuscript 
containing initial results of the qualitative research phase 
has been published.68
Quantitative methods
The quantitative phase of our study seeks to explore 
and quantify the determinants of vaccine hesitancy and 
underimmunisation with childhood and HPV vaccines 
in Switzerland. To this end, we developed questionnaires 
targeted at the different populations included in our 
study.
The questionnaires
As childhood and HPV vaccinations involve different 
populations and are generally viewed differently by 
patients, we survey two separate populations: parents of 
young children and youth (and their parents, if possible). 
In addition, we survey providers to gain a better under-
standing of views on vaccination in our diverse network 
of participating providers and the relationship between 
provider and patient views on vaccination.
To fully explore vaccine hesitancy and underimmuni-
sation in these diverse populations, we developed four 
separate questionnaires: (1) a childhood vaccination 
questionnaire to be administered to parents of young chil-
dren; (2) an HPV vaccination survey for youth; (3) an HPV 
vaccination survey for parents; and (4) a questionnaire 
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for providers. As Switzerland is a multilingual country, 
we developed versions of the questionnaire in the three 
main national languages, German, French and Italian. In 
addition, given the large number of immigrants living in 
Switzerland, we developed an English version of the ques-
tionnaire for those who preferred doing the interview in 
English.
Parent and youth surveys include questions about basic 
sociodemographic factors, including household composi-
tion, work and educational background, income, migra-
tion status and language knowledge. In order to maximise 
comparability with other surveys and to allow us to weight 
samples so that results are more representative, we drew 
these questions from two recent representative national 
surveys in Switzerland: the Swiss version of the European 
Social Survey 2014 (ESS 2014)69 and the 2012 Enquête 
Suisse de la Santé.70
As vaccine hesitancy is often correlated with political 
beliefs71 and religious beliefs,72 we also include a series of 
questions on political and religious beliefs and practices 
drawn from the ESS 2014. We include three questions 
on each theme. For religion, we ask about interviewees’ 
religious affiliation, the frequency with which they attend 
religious services and their perceptions of their own reli-
giosity. For political beliefs, we ask about interviewees’ 
level of interest in politics, which political party they feel 
close to and where they place themselves of a left- right 
political scale.
In addition, all questionnaires include the 20- item 
Moral Foundations Questionnaire73 based on the finding 
in a recent US study74 showing that moral foundations 
are associated with vaccine hesitancy. These survey items 
were all already extensively published and available in 
our survey languages and did not require translation or 
validation.
We measure underimmunisation through examination 
of participants’ vaccination records. We measure vaccine 
hesitancy using the 15- item Parent Attitudes about Child-
hood Vaccines (PACV) survey instrument, a validated 
measure of vaccine hesitancy and underimmunisation.75 
We use the original survey instrument for the childhood 
vaccination questionnaire and adapted questions to be 
appropriate to the target population for the parent and 
youth versions of the HPV questionnaire. For the provider 
questionnaire, we adapted the version of this instrument 
to measure vaccine hesitancy among childcare facility 
directors.76
Based on preliminary findings in the qualitative phase, 
we developed new questions around several themes, 
including (1) communication about vaccination with 
medical providers; (2) information sources consulted in 
vaccination decision- making; (3) perceptions about risk 
and control concerning possible exposure to vaccine- 
preventable diseases; and (4) the parent–provider 
relationship. For the HPV vaccination surveys, we also 
developed questions specific to this vaccine and its admin-
istration in Switzerland, including questions on knowl-
edge of HPV vaccine, sources of HPV vaccination and 
perceptions of school- based vaccination programmes. 
In addition, we ask both parents and youth a series of 
questions about health, including questions about health 
status, CAM usage and medical care usage. The provider 
questionnaire also asks for details about providers’ prac-
tices, particularly with regard to their practice of CAM. 
The questions we developed that are based on prelimi-
nary findings from the qualitative phase are listed in 
online supplementary appendix 1.
French, German and Italian versions of the PACV15 
were not available, so these questions and the new ques-
tions developed for these questionnaires were translated 
into French, German and Italian. Thirty- three key ques-
tions including the PACV and questions developed based 
on preliminary results of the qualitative portion of the 
study were translated using the forward and backward 
method. Two independent translators first translated into 
the target language (German, French or Italian) and then 
reconciled any disparities in their translations. Next, two 
different, independent translators who were blinded to 
the original questions translated them back into English.
Once developed, we pretested and piloted the child-
hood vaccination and HPV versions of our questionnaires 
in all languages. For the pretest, we recruited a conve-
nience sample of 61 individuals to test the questionnaires 
in all four survey languages. We pretested each version of 
the questionnaire with two to seven people and adjusted 
based on feedback. We then piloted the adjusted ques-
tionnaires using our full recruitment procedure (see 
‘Recruitment and survey populations’), conducting a 
further 56 interviews with the three questionnaires in the 
four survey languages. Finally, we pretested the provider 
questionnaire among providers in German, French and 
Italian. The questionnaire was also shared with the proj-
ect’s advisory board and adjusted based on their feedback.
Power analyses
Childhood vaccination survey
A conservative estimate is a proportion of 15% vaccine- 
hesitant parents in the practices of the participating 
biomedical and CAM providers combined (NB: 7% 
unvaccinated and 12% children with delayed vaccination 
were recorded in the 2012 FOPH survey).77 The sample 
size calculation aims at identifying the number of partici-
pants needed to detect a significant association of specific 
individual risk factors with vaccine hesitancy, which is 
here considered as a binary outcome. We further assume 
that factors potentially associated with vaccine hesitancy 
are prevalent in 20% of the population and that the OR 
between vaccine hesitancy and a relevant risk factor is 
at least 2. In this case, to detect a statistically significant 
association with such a risk factor at the level of 0.05 with 
a power of 0.8, 675 participants are needed. Due to the 
recruitment in selected provider practices, a certain clus-
tering of parents’ characteristics is to be expected for 
parents recruited in the same practice, in contrast to a 
simple random sample. To account for such clustering, 
a design effect of 2 is conservatively assumed, leading to 
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Figure 2 Network of participating providers. CAM, complementary and alternative medicine.
a total sample of 1350 parents to be interviewed. This 
would equally allow detecting a 10% lower proportion 
of vaccination among parents who are vaccine- hesitant 
compared with a vaccination rate of 90% in the remaining 
population.
HPV vaccination survey
To investigate vaccine hesitancy and associations with 
underimmunisation in the case of HPV vaccination, a 
separate sample of participants is required. Similar to 
the first case, we might also assume 15% vaccine- hesitant 
participants, and we further anticipate a 30% lower rate 
of vaccination among vaccine- hesitant persons than in 
the entire population. With a given prevalence of HPV 
vaccination of 53%, this would mean that among vaccine- 
hesitant persons only 37% would be vaccinated. With 
power=0.8 and alpha=0.05, a sample of 593 participants 
would be needed. To account for clustering, assuming a 
design effect of 2, the final sample would include 1186 
participants. However, more likely is a higher vaccine 
hesitancy rate of 30%, given the relative novelty of HPV 
vaccines and the fact that it has been recommended 
in boys/adolescents only for the past 3 years. With 
power=0.8 and alpha=0.05, a sample of 361 participants 
would be needed. To account for the cluster sample, 
assuming a design effect of 2, the final sample would 
include 722 participants.
Based on the above power analyses, our study popula-
tions include 1350 parents of children aged 0–11 for the 
childhood vaccination study and 722 young people aged 
15–21 years (for young women) or 15–26 years (for young 
men) for the HPV vaccination study.
As mentioned, there is regional and linguistic vari-
ation regarding vaccination uptake in Switzerland in the 
setting of different cantonal levels of school vaccination 
programmes39 78 and health authority support for vacci-
nation programmes.79 On the other hand, we expect the 
prevalence of vaccine hesitancy and of its determinants to 
be relatively homogeneous across different geographical 
and language regions of Switzerland. Therefore, we do 
not specifically take geographical and language hetero-
geneity into account for the outcome vaccine hesitancy. 
Moreover, conditional on this assumption being correct, 
the statistical power to detect an association between 
vaccine hesitancy and the likelihood of obtaining HPV 
vaccination would not be sizably smaller in the presence 
of geographical or language heterogeneity in HPV vacci-
nation rates than without such heterogeneity.
Recruitment and survey populations
We recruit our participants through the offices of the 
network of CAM and biomedical providers. As figure 2 
shows, our provider network includes more than 150 CAM 
and biomedical providers working in all three language copyright.
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regions in Switzerland and in almost every canton. Each 
dot represents a practice participating in the study: red 
dots represent CAM practitioners and blue dots biomed-
ical providers. To ensure confidentiality, we place dots in 
the correct canton but do not place them at the exact 
provider location. Group practices are represented by a 
single dot.
Providers are CAM or biomedical providers who treat 
children and/or youth and regularly deal with ques-
tions regarding vaccinations and vaccine decisions. They 
include paediatricians, general practitioners, gynaecolo-
gists, CAM physicians and CAM providers without formal 
medical training working independently or in group 
practices.
We interview parents and young people by telephone. 
Each telephone interview lasts approximately 30–35 min. 
Parents are recruited from urban and rural medical prac-
tices in French- speaking, German- speaking and Italian- 
speaking areas of Switzerland. In addition, we interview 
each participating provider in order to examine the rela-
tionships between provider perspectives, patient perspec-
tives and vaccine hesitancy. For the HPV portion of our 
study, we nterview one of the participating youth’s parents 
if the youth allow us to do so.
To be eligible to participate in the study, participants 
fulfil the following criteria. For the childhood vaccination 
substudy, parents are 18 years old or older with a child 
aged 0–11. For the quantitative HPV portion of our study, 
young women are between the ages of 15 and 21 (born 
between 1 July 1997 and 1 July 2003) and young men are 
between the ages of 15 and 26 (born between 1 July 1992 
and 1 July 2003). These differences are due to the timing 
of HPV vaccine recommendations for girls and boys. HPV 
vaccine reimbursement for girls 11–14 (target age) and 
15–19 (catch- up age) started 1 January 2008. HPV vacci-
nation reimbursement for males began on 1 July 2016 in 
Switzerland. Given the newness of this recommendation, 
we enrol youth males born between 1 July 1992 and 1 July 
2003 in order to gather data on all males aged 15–26 who 
have been eligible for the HPV vaccine through Swiss 
vaccine programmes. All study participants (parents, 
youth and providers) must speak one of the main Swiss 
national languages (French, German or Italian) or 
English.
We recruit all parents and youth through providers in 
order to be able to link the data from the parents with 
their provider’s data for a comparison by type of provider. 
We use a quota sampling technique as CAM providers 
are likely to see fewer patients per day. Our goal is to 
recruit a maximum of 20 parents of young children and 
a maximum of 15 youth per provider based on a rigorous 
sampling approach in a defined period. Recruitment 
targets for group practices are no more than three times 
the target for individual providers. Thus, targets in dual 
practices are 40 parents and 30 youth, and for practices 
with three or more providers, targets are 60 parents and 
45 youth. For every practice, the total number of eligible 
patients in a specific time period will be established, 
which allows post- hoc weighting to the known total of 
eligible patients in this time period.
Given the diversity of providers and differences in our 
study subpopulations, we employ a variety of recruit-
ment techniques. In large practices or practices with 
high patient volume, interviewers recruit participants 
directly in providers’ waiting rooms. Interviewers are 
medical students trained in recruiting participants, 
obtaining informed consent, conducting quantitative 
interviews over the telephone and quantitative data 
management. For inoffice recruitment, interviewers 
spend 2–5 days in providers’ waiting rooms, with the 
goal of recruiting a maximum of 20 parents and/or 
a maximum of 15 youth for interviews. Interviewers 
contact all eligible patients to present the study and 
ask whether they are interested in participating. For 
those who agree, interviewers obtain informed consent 
and a copy of the vaccination certificate (if possible) in 
waiting rooms and then arrange to conduct a telephone 
interview at a later time. In large group practices, inter-
viewers have the option to work as a team to manage 
particularly high patient volumes.
In smaller practices or practices with lower patient 
volumes for the targeted groups, we ask providers to recruit 
participants retrospectively by reviewing their patient log 
from the last 2–6 months and contacting eligible patients 
to see if they would be interested in participating in the 
study. Providers transmit a detailed record of attempted 
contacts and take note of refusals and interested parties. 
We then contact those who indicate an interest by phone 
to present the study, obtain informed consent and a copy 
of the vaccination certificate (if possible), and arrange for 
a telephone interview. Interviewers select potential partic-
ipants randomly from the lists provided until they have 
the required quota of participants in each group.
Interviewers determine the most appropriate recruit-
ment technique during a first visit with the provider. As 
some providers may have high volumes of one population 
and low volumes of another (eg, paediatricians may see 
many young children but few youths 15 of age or over), 
we may employ different recruitment methods for the 
different subsamples.
Experience to date shows that providers generally 
accept our preferred recruitment practice for their type 
of practice. However, we work with providers to find work-
able solutions if they are uncomfortable with or unable 
to accommodate our standard recruitment procedures. 
Although small practices, particularly for CAM providers, 
are often hesitant to let interviewers recruit in waiting 
rooms, such practices rarely have sufficient patient 
volume to merit that approach. Very few large- volume 
providers have been unwilling to allow interviewers to 
recruit in waiting rooms; however, when they are, we 
implement the provider recruitment practice used in 
smaller practices. More commonly, practices do not have 
the capacity to review patient logs and contact patients. 
In that case, as approved by the local ethics commis-
sions, interviewers can assist medical providers and their 
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assistance in reviewing logs and contacting patients from 
providers’ offices.
For all recruitment techniques, we track how many 
people were contacted, how many agreed to participate 
or be contacted again, how many gave consent to inter-
views, and how many completed interviews. This informa-
tion will allow us to assess the refusal rate, the dropout 
rate and the number of individuals lost to follow up.
Additionally, we conduct a quantitative telephone or 
face- to- face survey with all participating providers during 
the quantitative component of the study in order to quan-
titatively assess if providers’ vaccine perspectives are asso-
ciated with those of their patients.
Quantitative data analysis
The following are our primary quantitative research 
questions:
 ► What are the determinants of vaccine hesitancy for 
childhood and HPV vaccinations in Switzerland?
 ► What is the relationship between vaccine hesitancy 
and underimmunisation?
We measure vaccine hesitancy based on the PACV 
score. As this instrument has not previously been used 
in Switzerland or in our survey languages, we first test its 
validity for Switzerland using Mokken Scale analysis to 
confirm the unidimensionality of the scale. Individuals 
with a PACV score of ≥50 are considered vaccine- hesitant, 
and individuals with a PACV score <50 are not consid-
ered vaccine- hesitant.75 We will use multilevel logistic 
regression to assess the influence of different variables on 
vaccine hesitancy. We will explore associations between 
vaccine hesitancy and a number of individual- level char-
acteristics, including age, sex, household composition, 
place of birth, immigration status, household income, 
employment status and work hours, daycare usage, 
highest achieved level of education, political affiliations, 
religion, CAM usage, trust in medical providers and satis-
faction with consultations, sources of information about 
vaccination consulted, views on parents’ role in vaccine 
decisions, views of importance of health, views of risks of 
vaccine- preventable diseases, and moral foundations. In 
addition, our research design allows us to explore how 
factors at higher levels are associated with vaccine hesi-
tancy, including how vaccine hesitancy varies by canton 
and language region and by provider or by various 
provider characteristics (CAM vs biomedical providers), 
and to what extent vaccine hesitancy of the parent/youth 
correlates with vaccine hesitancy of the provider. Finally, 
although our data are not representative, we can weight 
results to allow us to roughly estimate the prevalence of 
vaccine hesitancy in Switzerland.
study status
This study is ongoing, with some parts of the research 
completed, others ongoing and others yet to begin. For the 
qualitative portion of the study, we have completed quali-
tative interviews with biomedical and CAM providers and 
ethnographic observations of vaccination consultations. 
We have also completed qualitative interviews with parents 
of young children. Qualitative interviews with youth and 
parents focusing on HPV vaccination are ongoing. We are 
at the recruitment stage for our qualitative research on 
HPV vaccination at schools and with public health offi-
cials. Finally, we are compiling a list of vaccination infor-
mation sources based on responses to questions related to 
this subject in the quantitative questionnaires and discus-
sions in qualitative interviews with parents and youth. We 
will begin analysis once this list in complete, at the end 
of data collection for qualitative interviews and the ques-
tionnaires. For the quantitative portion of our study, we 
have completed questionnaire design and testing and the 
power analysis to determine sample size. We are currently 
recruiting and interviewing parents, youth and providers 
for the survey, with approximately half of interviews 
completed. We continue to recruit providers as well.
dIsCussIon
By using a sequential exploratory mixed- methods study 
design,52 this study will provide rich and multifaceted data 
on vaccination decision- making and vaccine hesitancy in 
Switzerland. In line with such a study design, the quali-
tative data informed the tools used for the quantitative 
data collection component. The results of both qualita-
tive and quantitative components of our study will likely 
be complementary to one another and will allow us to 
answer different types of research questions. That said, 
any discrepancies or contradictory findings between the 
qualitative and quantitative components will merit further 
investigation, which we will highlight in the dissemina-
tion of study results. Additionally, given the multifaceted 
nature of vaccine hesitancy and health decision- making 
and the study’s exploratory mixed- methods study design, 
the results from both qualitative and quantitative compo-
nents will provide us with rich and detailed data for the 
Swiss context, where there is limited available data.
A particular strength of this study is its focus on perspec-
tives of both medical providers and their patients. Studies 
have shown that providers remain a trusted source of 
information for parents and youth facing vaccine deci-
sions, so a greater understanding of provider perspectives 
is important.25–32 Another major strength of this study is its 
inclusion of the perspectives of both CAM and biomedical 
providers. While a growing literature explores the associ-
ation between vaccine hesitancy and CAM usage,6 12 19 20 
few studies include the perspective of CAM providers and 
none that we know of has the extent of cooperation with 
CAM providers found here.
Qualitative interviews provide key insights into parents, 
youths, and CAM and biomedical providers’ perspectives 
on vaccination. In addition, interviews with CAM and 
biomedical providers shed light onto their views on vacci-
nation, vaccine- hesitant patients and how they interact 
with this population in their practices. Observations of 
vaccine consultations in offices provide another opportu-
nity to get a sense of the variety of approaches providers 
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employ when broaching the subject of vaccination. The 
combination of qualitative interviews with numerous 
stakeholders in vaccine decision- making and planning, 
ethnographic observations of vaccination consultations 
and school information sessions about the HPV vaccina-
tion, and qualitative analysis of vaccination information 
sources allows for qualitative triangulation into the multi-
faceted phenomenon of vaccine hesitancy in Switzerland. 
Such a triangulation of qualitative data through multiple 
qualitative methods allows us to better understand the 
‘multiple realities’ of medical consultations,67 in addi-
tion to allowing us to explore how various actors interact 
with and perceive the Swiss health system in regard to 
vaccination.
Although data are not strictly representative of Switzer-
land, data from the quantitative survey gives us a sense of 
the overall prevalence of vaccine hesitancy in Switzerland 
and how this varies between language regions, cantons, 
and urban, suburban and rural settings. More impor-
tantly, it allows us to explore the association of vaccine 
hesitancy with other factors, like CAM usage, religion 
and spirituality, moral foundations, and political orien-
tation. In addition, by pairing data from providers and 
their patients, we can see whether there is an association 
between providers’ and patients’ views on vaccines. The 
quantitative data also provides us with insight into the 
major sources of information parents and youth draw on 
when making vaccination decisions. Finally, the mixed- 
methods study design allowing for the qualitative compo-
nent to inform the quantitative component also allows us 
to triangulate both the qualitative and quantitative data 
gathered throughout the duration of the study so that 
results from both components can be compared.
Limitations
There are several limitations to the various parts of our 
study. A major limitation, which we also argue should 
be seen as a study strength, comes from our focus on 
recruiting participants through providers. This technique 
has major advantages when seeking to examine effects of 
provider characteristics on patient beliefs and behaviours, 
particularly for a topic such as vaccine hesitancy where 
trust between patients and providers has been shown 
to be a major determinant.32 We also included items in 
both qualitative interview guides and quantitative ques-
tionnaires in order to gauge to what extent patients select 
physicians they trust or whose practices or attitudes align 
with their own, a patient practice which has been docu-
mented in vaccine hesitancy literature.80 These questions 
also allow us to assess if disagreements between patients 
and providers have brought patients to seek care else-
where in more provider- driven selection processes.
The quantitative component recruitment strategy 
indicates that populations that do not regularly see 
medical providers are under- represented in our data. 
While universal health insurance requirements attempt 
to ensure that most people living in Switzerland have 
access to healthcare, certain populations are still 
under- represented, including recent migrants and undoc-
umented populations. Recruiting through providers 
poses further questions of selection bias, as people who 
see doctors more often are more likely to participate in 
our study. This bias means that, for example, parents of 
infants were more apt to be recruited than parents of 
older children, as infants see the doctor more regularly. 
Selection bias problems are particularly relevant to youth 
populations, as most youth are healthy and thus among 
the least likely to regularly seek medical care. As such, 
youth in our study may differ in important ways from 
youth in Switzerland overall. In addition, as our provider 
network was established through personal recruitment by 
members of the study team and snowball sampling, the 
network itself is not representative and subject to selec-
tion bias. In our view, the advantages of being able to link 
provider and patient data outweighed these limitations.
For qualitative interviewing, interviewer effects may 
affect the type and quality of information we received; 
interviews and observations are conducted by a male 
medical sociologist trained in qualitative research 
methods, a female medical doctor trained in qualita-
tive research methods, a female senior medical student 
with qualitative research training, and a female medical 
anthropologist trained in qualitative research methods. 
That being said, having a variety of researchers with 
different backgrounds involved in the data collection 
and analytical process adds to the richness of the anal-
ysis through clarification of concepts during indepth 
research team discussions. Another limitation arises from 
the way we observed vaccine discussions. Observers watch 
the discussion in person and take notes, but do not audio- 
record or video- record discussions. The absence of such 
recordings limits our ability to rigorously analyse the 
conversations, while the physical presence of observers in 
the consultation may have had an effect on discussions. 
Furthermore, given that the data are collected in both 
French- speaking and German- speaking regions of Swit-
zerland, we have a multilingual corpus which necessitates 
indepth discussions between study members during qual-
itative data analysis.
Furthermore, as noted above, the quantitative study is 
not based on a representative sample but instead allow-
susto compare results between different types of providers 
and their patients, and between different sociocultural 
regions of Switzerland. As in the qualitative component, 
interviewer effects may affect the type and quality of infor-
mation we received. We will include data quality controls 
into data analysis in order to check for interviewer effects. 
Additionally, linguistic barriers, particularly with recent 
migrants to Switzerland, may prove challenging for 
participants to provide accurate responses to our inter-
view questions.
scientific relevance
Vaccine hesitancy is a complex public health issue 
in high- income countries, yet there is no agreed- on 
measure of vaccine hesitancy. Multilingual, validated 
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instruments for measuring vaccine hesitancy are rare, 
making comparative study difficult. This study develops 
and test translations of the 15- item PACV in three new 
languages and provides valuable assessments of vaccine 
hesitancy in French- speaking, German- speaking and 
Italian- speaking contexts. Furthermore, our study design 
includes vaccination certificates in order to statistically 
examine the relationship between vaccine hesitancy and 
underimmunisation.
Results from the study make a contribution to the 
literature on the relationship between CAM usage and 
vaccine hesitancy. The combination of rich qualitative 
data including both biomedical and CAM perspectives 
and provider- linked data from patients who see CAM 
practitioners allows for a more indepth examination of 
this relationship than found in the literature to date.
A combination of the data collected through the quanti-
tative and qualitative methods and their analysis will form 
the necessary background for the design, submission and 
implementation of an appropriate randomised control 
trial intervention designed at improving vaccine commu-
nication and counselling among physicians, parents and 
adolescents in Switzerland.
Patient and public involvement
Study participants, both patients and medical providers, 
are involved in the study design throughout the dura-
tion of the data collection. Study tools are piloted and 
tested by the research team who requests patient and 
provider input during this process. Participants are given 
the opportunity to indicate any additional comments 
throughout data collection so that we may take their prior-
ities, experiences and preferences into account. Patients 
(parents and adolescents) and providers assist us in addi-
tional recruitment efforts as described in the Methods 
and design section. All participants were informed of the 
amount of time their participation would entail prior to 
data collection. We systematically request participants’ 
wishes to receive the results of the study by including 
an item on the consent form allowing them to provide 
us with their contact information. We will send relevant 
published results to study participants and invite them to 
public forums where we discuss our study results.
EthICs And dIssEMInAtIon
As approved by the ethics committee, all questionnaire 
items include ‘do not wish to answer’ categories, given 
the personal and sensitive nature of certain questions, in 
particular those regarding religion and political views. 
In accordance with the Human Research Act (HRA), 
adolescents (defined as individuals 14 years of age or 
older) who are capable of judgement are able to provide 
informed consent in writing and do not need to provide 
informed consent in writing from a legal representative 
‘if the research project entails more than minimal risks 
and burdens’ (HRA, Art 23, Par 1). Ethikkommission 
Nordwest- und Zentralschweiz has approved of this study 
as entailing less than minimal risks and burdens and thus 
does not require informed consent in writing from a legal 
representative for adolescents. Informed consent from 
minor participants (all aged 15 years and older for this 
study) is obtained directly from the participants and not 
their legal representatives.
Study results will be published in peer- reviewed 
academic journals and disseminated to healthcare profes-
sionals, researchers and the public via academic confer-
ences and public presentations. The data sets used and/
or analysed during the current study are available from 
the corresponding author on reasonable request.
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